These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
30. Non-small cell lung cancer: detection of early response to chemotherapy by using contrast-enhanced dynamic and diffusion-weighted MR imaging. Yabuuchi H, Hatakenaka M, Takayama K, Matsuo Y, Sunami S, Kamitani T, Jinnouchi M, Sakai S, Nakanishi Y, Honda H. Radiology; 2011 Nov; 261(2):598-604. PubMed ID: 21852569 [Abstract] [Full Text] [Related]
31. Hypertension as a biomarker in patients with recurrent glioblastoma treated with antiangiogenic drugs: a single-center experience and a critical review of the literature. Lombardi G, Zustovich F, Farina P, Fiduccia P, Della Puppa A, Polo V, Bertorelle R, Gardiman MP, Banzato A, Ciccarino P, Denaro L, Zagonel V. Anticancer Drugs; 2013 Jan; 24(1):90-7. PubMed ID: 23075631 [Abstract] [Full Text] [Related]
34. Glioblastoma: a method for predicting response to antiangiogenic chemotherapy by using MR perfusion imaging--pilot study. Sawlani RN, Raizer J, Horowitz SW, Shin W, Grimm SA, Chandler JP, Levy R, Getch C, Carroll TJ. Radiology; 2010 May; 255(2):622-8. PubMed ID: 20413772 [Abstract] [Full Text] [Related]
35. Identification of Early Response to Anti-Angiogenic Therapy in Recurrent Glioblastoma: Amide Proton Transfer-weighted and Perfusion-weighted MRI compared with Diffusion-weighted MRI. Park JE, Kim HS, Park SY, Jung SC, Kim JH, Heo HY. Radiology; 2020 May; 295(2):397-406. PubMed ID: 32154775 [No Abstract] [Full Text] [Related]
38. The Impact of T2/FLAIR Evaluation per RANO Criteria on Response Assessment of Recurrent Glioblastoma Patients Treated with Bevacizumab. Huang RY, Rahman R, Ballman KV, Felten SJ, Anderson SK, Ellingson BM, Nayak L, Lee EQ, Abrey LE, Galanis E, Reardon DA, Pope WB, Cloughesy TF, Wen PY. Clin Cancer Res; 2016 Feb 01; 22(3):575-81. PubMed ID: 26490307 [Abstract] [Full Text] [Related]